We recently compiled a list of the Louis Navellier’s Top 10 Stock Picks Heading into 2025. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against Louis Navellier’s other stock picks.
Louis Navellier, Chairman and Founder of Navellier & Associates, is a renowned American investor who is celebrated for his skill in navigating the stock market and delivering impressive profits. Leading a firm dedicated to growth investments, Navellier’s strategy is reflected in his high-performing portfolio. His journey began in a college mainframe computer lab in the 1970s. While studying at the now Cal State East Bay, Navellier set out to validate the prevailing belief that beating the market was impossible. His original aim was to create an index product before index investing became mainstream, attempting to replicate the S&P 500. Ironically, his project failed by succeeding. Rather than simply matching the market, his model consistently outperformed it, uncovering inefficiencies that became the cornerstone of his investment philosophy. In 1987, Navellier would go on to establish Navellier & Associates, a fund dedicated to providing customized portfolio strategies aimed at maximizing returns while effectively managing risk for individual investors.
With decades of expertise in translating academic theories into real-world market strategies, Louis Navellier champions a disciplined approach to quantitative analysis for identifying market-beating stocks. His methodology follows a meticulous three-step process: quantitative analysis to pinpoint high-potential opportunities, fundamental analysis to evaluate each candidate’s financial health and growth prospects, and portfolio optimization to fine-tune the selection for maximum performance. Throughout his career, Navellier has identified numerous “thousand-percent winners,” from Conair’s dominance in the hair dryer market during the 1980s to NVIDIA’s leadership in AI chips today. His methodology emphasizes discovering well-managed companies that lead their industries, particularly those with expanding operating margins and steady earnings growth.
Navellier’s U.S. Outlook
In a Market 360 article, Louis Navellier offered insights into the recent presidential election and its potential market implications under a Trump 2.0 administration. He highlighted the critical role manufacturing played in the 2024 election outcome by pointing to the Institute of Supply Management’s (ISM) report, which revealed a decline in the manufacturing index to 46.5 in October from 47.2 in September, signaling contraction (any reading below 50). The details paint an even grimmer picture: The Bureau of Labor Statistics’ payroll report has revised August and September job figures downward by a combined 112,000. As such, manufacturing took a significant hit, with 46,000 jobs lost, partly due to Boeing’s ongoing challenges. Here’s what Navellier had to say about the report:
“All in all, this payroll report was a statistical mess and will likely need to be revised when we have more information. But it also drove Treasury yields lower and increased pressure on the Federal Reserve to cut key interest rates, since the Fed is now more worried about the job market than inflation.”
According to Navellier, the new administration is expected to drive growth in the manufacturing sector through a combination of measures: implementing tariffs to counter unfair overseas competition, encouraging the Federal Reserve to maintain lower interest rates, and leveraging cheaper energy prices that position the U.S. favorably compared to Europe and Japan. He noted that if these strategies succeed, the U.S. could see a manufacturing boom.
On the other hand, Navellier has been one of the biggest heralds of AI and its implications. Currently, many investors remain heavily focused on the “first generation” of AI stocks and while Wall Street’s AI darling is likely to continue generating returns, Navellier states that it has become yesterday’s story. According to the investor, the real opportunity lies in the “second generation” of AI stocks; companies poised to harness generative AI to build profitable enterprises and revolutionize existing industries. This next wave will usher in transformational change of a kind that happens only once every 25 years. The companies that adapt to this second wave of AI will soar, delivering years of outperformance. Those that fail to embrace this shift risk falling behind—or even disappearing altogether. Conversely, Navellier believes that AI will also dismantle outdated industries and businesses. The “Real AI Boom”, as he calls it, will mint new millionaires—and even billionaires—while driving hundreds, if not thousands, of stocks worldwide to collapse.
Our Methodology
For this analysis, we examined Navellier & Associates’ stock portfolio from the third quarter of 2024. The stocks are ranked based on the firm’s stake value in each holding.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
An array of pharmaceutical pills with the company’s logo on the bottle.
Eli Lilly and Company (NYSE:LLY)
Navellier & Associates’ Stake Value: $22.12 million
Number of Hedge Funds Holders: 106
Eli Lilly & Company (NYSE:LLY) is a leading global pharmaceutical company that develops, manufactures, and sells a broad range of medications. Founded in 1876, it has grown into one of the world’s largest pharmaceutical firms.
Eli Lilly & Company (NYSE:LLY) saw significant growth in its third-quarter earnings, with a 42% increase in revenue, driven primarily by strong sales of its diabetes and cancer drugs, Mounjaro and Zepbound, which collectively exceeded $3 billion. Earnings per share also rose to $1.18, compared to just $0.10 in the same quarter last year.
Looking forward, the pharma giant raised its revenue guidance to between $45.4 billion and $46 billion, projecting 50% growth in the fourth quarter. The company’s strategic investments, including $2 billion in Ireland and $4.5 billion for the Lilly Medicine Foundry in Indiana, have been crucial to its ongoing expansion.
At the end of October, Truist Securities slightly adjusted its price target for Eli Lilly & Company (NYSE:LLY) shares to $1,029, down from $1,033, while maintaining a Buy rating. The adjustment reflects Eli Lilly’s recent performance and market conditions, with Truist highlighting sustained demand for its type 2 diabetes and obesity treatments as key growth drivers.
Overall LLY ranks 3rd on our list of Louis Navellier’s top stock picks heading into 2025. While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that certain AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article is originally published at Insider Monkey.
